VEGFR2 is selectively expressed by FOXP3high CD4+ Treg

Hiroyuki Suzuki, Hideya Ohnishi, Junji Wada, Akio Yamasaki, Haruo Tanaka, kenji nakano, Takashi Morisaki, Mitsuo Katano

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

CD25+ FOXP3+CD4+ T cells (Treg) have been considered to play an important role in immune tolerance against several tumor antigens. It has also been indicated that high-level expression of FOXP3 (FOXP3high) is sufficient to confer suppressive activity to normal non-Treg. Here, we showed for the first time that vascular endothelial growth factor receptor 2 (VEGFR2) is selectively expressed by FOXP3high but not FOXP3low Treg. Such VEGFR2+ Treg exist in several tissues including PBMC and malignant effusion-derived lymphocytes. In conclusion, VEGFR2 may be a novel target for controlling Treg with highly suppressive function.

Original languageEnglish
Pages (from-to)197-203
Number of pages7
JournalEuropean Journal of Immunology
Volume40
Issue number1
DOIs
Publication statusPublished - Jan 1 2010

Fingerprint

Vascular Endothelial Growth Factor Receptor-2
Immune Tolerance
Neoplasm Antigens
Lymphocytes
T-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Suzuki, H., Ohnishi, H., Wada, J., Yamasaki, A., Tanaka, H., nakano, K., ... Katano, M. (2010). VEGFR2 is selectively expressed by FOXP3high CD4+ Treg. European Journal of Immunology, 40(1), 197-203. https://doi.org/10.1002/eji.200939887

VEGFR2 is selectively expressed by FOXP3high CD4+ Treg. / Suzuki, Hiroyuki; Ohnishi, Hideya; Wada, Junji; Yamasaki, Akio; Tanaka, Haruo; nakano, kenji; Morisaki, Takashi; Katano, Mitsuo.

In: European Journal of Immunology, Vol. 40, No. 1, 01.01.2010, p. 197-203.

Research output: Contribution to journalArticle

Suzuki, H, Ohnishi, H, Wada, J, Yamasaki, A, Tanaka, H, nakano, K, Morisaki, T & Katano, M 2010, 'VEGFR2 is selectively expressed by FOXP3high CD4+ Treg', European Journal of Immunology, vol. 40, no. 1, pp. 197-203. https://doi.org/10.1002/eji.200939887
Suzuki, Hiroyuki ; Ohnishi, Hideya ; Wada, Junji ; Yamasaki, Akio ; Tanaka, Haruo ; nakano, kenji ; Morisaki, Takashi ; Katano, Mitsuo. / VEGFR2 is selectively expressed by FOXP3high CD4+ Treg. In: European Journal of Immunology. 2010 ; Vol. 40, No. 1. pp. 197-203.
@article{0e4c71a590e74dc78e95afcd4d4c18cb,
title = "VEGFR2 is selectively expressed by FOXP3high CD4+ Treg",
abstract = "CD25+ FOXP3+CD4+ T cells (Treg) have been considered to play an important role in immune tolerance against several tumor antigens. It has also been indicated that high-level expression of FOXP3 (FOXP3high) is sufficient to confer suppressive activity to normal non-Treg. Here, we showed for the first time that vascular endothelial growth factor receptor 2 (VEGFR2) is selectively expressed by FOXP3high but not FOXP3low Treg. Such VEGFR2+ Treg exist in several tissues including PBMC and malignant effusion-derived lymphocytes. In conclusion, VEGFR2 may be a novel target for controlling Treg with highly suppressive function.",
author = "Hiroyuki Suzuki and Hideya Ohnishi and Junji Wada and Akio Yamasaki and Haruo Tanaka and kenji nakano and Takashi Morisaki and Mitsuo Katano",
year = "2010",
month = "1",
day = "1",
doi = "10.1002/eji.200939887",
language = "English",
volume = "40",
pages = "197--203",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "Wiley-VCH Verlag",
number = "1",

}

TY - JOUR

T1 - VEGFR2 is selectively expressed by FOXP3high CD4+ Treg

AU - Suzuki, Hiroyuki

AU - Ohnishi, Hideya

AU - Wada, Junji

AU - Yamasaki, Akio

AU - Tanaka, Haruo

AU - nakano, kenji

AU - Morisaki, Takashi

AU - Katano, Mitsuo

PY - 2010/1/1

Y1 - 2010/1/1

N2 - CD25+ FOXP3+CD4+ T cells (Treg) have been considered to play an important role in immune tolerance against several tumor antigens. It has also been indicated that high-level expression of FOXP3 (FOXP3high) is sufficient to confer suppressive activity to normal non-Treg. Here, we showed for the first time that vascular endothelial growth factor receptor 2 (VEGFR2) is selectively expressed by FOXP3high but not FOXP3low Treg. Such VEGFR2+ Treg exist in several tissues including PBMC and malignant effusion-derived lymphocytes. In conclusion, VEGFR2 may be a novel target for controlling Treg with highly suppressive function.

AB - CD25+ FOXP3+CD4+ T cells (Treg) have been considered to play an important role in immune tolerance against several tumor antigens. It has also been indicated that high-level expression of FOXP3 (FOXP3high) is sufficient to confer suppressive activity to normal non-Treg. Here, we showed for the first time that vascular endothelial growth factor receptor 2 (VEGFR2) is selectively expressed by FOXP3high but not FOXP3low Treg. Such VEGFR2+ Treg exist in several tissues including PBMC and malignant effusion-derived lymphocytes. In conclusion, VEGFR2 may be a novel target for controlling Treg with highly suppressive function.

UR - http://www.scopus.com/inward/record.url?scp=74249123434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74249123434&partnerID=8YFLogxK

U2 - 10.1002/eji.200939887

DO - 10.1002/eji.200939887

M3 - Article

C2 - 19902430

AN - SCOPUS:74249123434

VL - 40

SP - 197

EP - 203

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 1

ER -